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ESMO Minimum Clinical Recommendations for diagnosis,
treatment and follow-up of soft tissue sarcomas
Incidence
. The crude incidence of soft tissue sarcoma in the European
Union is 1.0–3.0/100 000 per year, the mortality 0.6–
0.8/100 000 per year. They are diagnosed at any age but are
more frequent in older patients with a peak incidence at the
age of 50 years.
Diagnosis
. Histological diagnosis and evaluation of grades are prefer-
entially made on an incisional surgical biopsy or on the
completely resected tumor. Tru-cut biopsies are also used
but should be restricted to experienced centers.
. Gastrointestinal stromal tumors should be confirmed by
staining for CD117.
. Specific types of small round cell tumors (extra-osseous
Ewing’s sarcoma, embryonal rhabdomyosarcoma) should be
identified by immunohistochemistry and cytogenetics and
be treated accordingly.
Staging and risk assessment
. Staging is performed by physical exam and the appropriate
radiological techniques. To exclude lung metastases a CT
scan is recommended in operable patients.
. For staging according to the UICC/AJCC 2002 system,
tumor size is categorized as small (<_5 cm, T1) or large (T2)
and is complemented by information about location (super-
ficial: Ta or deep: Tb) and histological grade (using either
of the grading systems G1-4 or G1-3 or low/high) as further
parameters that are required for the stage grouping are
shown in Table 1.
Treatment plan
. Soft tissue sarcoma requires a multidisciplinary approach by
an experienced team.
Surgery
. Surgery is the main treatment for localized disease. The
tumor should be removed by wide excision or by compart-
mental resection including the cutaneous scar and tractus of
a previous biopsy. The width of the resection might
be decreased in case of resistant anatomic planes such as
muscular fasciae, periostium, perineurium, if not infiltrated.
. After wide excision of high-grade sarcomas, adjuvant radi-
ation therapy is recommended [II, B].
. In case of radical surgery obtained by compartmental exci-
sion or amputation at a large distance from the primary
tumor, adjuvant radiation therapy is not necessary.
. Re-operation is recommended in case of previous marginal
or intralesional resection [III, B].
. In case of completely resectable lung metastases, surgery
has to be considered [III, B].
Radiation therapy
. Radiation therapy should be administered postoperatively at
a dose of 60–65 Gy with a shrinking field technique in case
of wide resection [II, B].
. In selected patients preoperative radiotherapy may be an
option [III, B].
Chemotherapy
Localized disease:
. Preoperative chemotherapy is not standard practice for oper-
able patients [III, B]. It can be considered together with
radiotherapy in patients with borderline resectable tumors.
. Adjuvant chemotherapy is not standard practice even though
it might improve distant and local control. Its impact on
overall survival is still debated [II, A]. It may be considered
in younger patients with large and high-grade tumors [II,
C].
. In non-resectable tumors confined to an extremity, che-
motherapy with or without radiotherapy or isolated
hyperthermic limb perfusion with chemotherapy and/or
cytokines offers an alternative to amputation [III, B ].
Metastatic disease:
. Chemotherapy is the standard treatment for metastatic dis-
ease. Doxorubicin with or without ifosfamide is commonly
Table 1.
Stage Primary
tumor
Lymph
nodes
Distant
metastases
Grading G1 – 4
(or G1 – 3 or low / high)
IA T1a or b N0 or x M0 G1-2 (or G1 or low)
IB T2a or b N0 or x M0 G1-2 (or G1 or low)
IIA T1a or b N0 or x M0 G3-4 (or G2-3 or high)
IIB T2a N0 or x M0 G3-4 (or G2-3 or high)
III T2b N0 or x M0 G3-4 (or G2-3 or high)
IV Any T N1 M0 Any G
Any T Any N M1 Any G
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used. Doxorubicin alone seems to be equivalent to its com-
binations with other agents with regard to survival, despite a
higher response rate with combination regimens [II, B].
. Imatinib (STI 571, a tyrosine kinase receptor inhibitor) is
the treatment of choice for gastro-intestinal stromal tumors
(GIST).
Response evaluation
. Response evaluation of chemotherapy for metastatic disease
should be performed after 2 or 3 cycles with the radiologi-
cal exams that were positive before treatment.
Follow-up
. Early detection of recurrence might influence the possibility
of a curative therapy. The patients should be followed every
3 months with history and physical examination. MRI of the
site of resection of the primary tumor is proposed twice a
year for the first 2–3 years and then once a year. For
patients with high-grade tumors a chest X-ray is rec-
ommended every 3 to 4 months in the first 2–3 years, twice
a year up to the 5th year, and once a year thereafter [IV, B].
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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